New patents boost Myriad as legal battle continues
This article was originally published in Clinica
Executive Summary
In a busy week for Myriad Genetics, the US company reinforced its diagnostic patent claims for the BRCA1 breast cancer gene and sent a further warning shot at rival OncorMed.